Google_______________

Kidney Stones are a Possible, but Uncommon, Side Effect of Atazanavir (Reyataz)

By Liz Highleyman

Kidney stones, or nephrolithiasis, are a potential side effect of certain antiretroviral drugs, notably indinavir (Crixivan). Stones can occur when a drug precipitates and forms crystals in the kidneys. Symptoms include severe flank pain and blood in the urine.

In the May 31, 2007 issue of AIDS, scientists from the Food and Drug Administration's Center for Drug Evaluation and Research Division of Antiviral Products summarized reported cases of nephrolithiasis in people taking atazanavir (Reyataz).


The authors searched the agency's Adverse Event Reporting System -- which collects voluntary reports from clinicians and patients -- for reports of kidney stones in HIV-infected individuals using atazanavir-based regimens. A total of 30 cases were identified over a 4-year period (December 2002 through January 2007).

Of the 30 cases, 21 were in men, 5 were in women, and 4 were not specified; 5 patients had a known prior history of kidney stones. Interestingly, of the 20 cases that included complete information about the patient's HIV treatment, 13 were also taking tenofovir (Viread, also a component of the fixed-dose pills Truvada and Atripla), which has been associated in some studies with impaired kidney function.

Several of the patients required hospitalization for management, including lithotripsy (use of shock waves to break up kidney stones), ureteral stent insertion, or endoscopic stone removal. Some cases of nephrolithiasis resulted in atazanavir discontinuation.

While this adverse event appears to be uncommon overall, the authors wrote that, "Healthcare professionals and patients should be informed that nephrolithiasis is a possible adverse event with atazanavir."

Manufacturer Bristol-Myers Squibb has revised the drug's package insert to include the potential for this side effect.

06/22/07

Reference
KM Chan-Tack, MM Truffa, KA Struble, and others. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 21(9): 1215-1218. May 31, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Index of All HIV and AIDS
Articles by Topic ( A to Z)


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase (amprenavir)
Aptivus (tipranavir)
Crixivan (indinavir)
Fortovase (saquinavir soft gel)
Invirase (saquinavir hard gel)
Kaletra (lopinavir/ritronavir)
Lexiva
(Fosamprenavir)
Norvir (ritonavir)
Prezista
(darunavir)
Reyataz (atazanavir)
Viracept
(nelfinavir)

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir (AZT+ 3TC)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Hivid (zalcitabine; ddC)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (Tenofovir / Emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor (delavirdine)

Sustiva (efavirenz)
Viramune (nevirapine)

Entry Inhibitors
Fuzeon (enfuvirtide; T-20)

Fixed-dose Combinations
Atripla
(efavirenz + emtricitabine + tenofovir)
Combivir
(retrovir + lamivudine)

Trizivir
(abacavir + zidovudine + lamivudine)
Truvada
(tenofovir + emtricitabine)